Natco Pharma’s board approves a rights issue to raise up to ₹1,279.35 crore, according to a regulatory filing cited by outlets. The company plans to issue up to 170,58,082 equity shares with a face value of ₹2 each. The issue price is set at ₹750 per share, and the total proceeds are capped at the stated amount.
The reporting aligns on the size and pricing of the issue, but the available excerpts focus mainly on the approval and the fundraising structure rather than broader details such as the purpose of funds, record date, or subscription terms. One outlet frames the transaction as an approval by the board to raise up to the specified ceiling, while another describes the same plan as an effort to raise ₹1,279 crore via a rights issue. Both accounts reference the same overall quantum and share issuance plan.
